Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Niels Jongs(University Medical Center Groningen), Tom Greene(University of Utah), Glenn M. Chertow(Stanford University), John J.V. McMurray(University of Glasgow), Anna Maria Langkilde(AstraZeneca (Sweden)), Ricardo Correa‐Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Peter Rossing(Steno Diabetes Center), C. David Sjöström(AstraZeneca (Sweden)), Bergur V. Stefánsson(AstraZeneca (Sweden)), Robert D. Toto(The University of Texas Southwestern Medical Center), David C. Wheeler(University College London), Hiddo J.L. Heerspink(University Medical Center Groningen)
The Lancet Diabetes & Endocrinology
October 5, 2021
10.1016/s2213-8587(21)00243-6
Cited by 202Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis